Mario Negri Institute for Pharmacological Research: Kidney Diseases trials

The registry lists 16 Kidney Diseases studies with Mario Negri Institute for Pharmacological Research as lead sponsor. 1 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 7Phase 3 4No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• New Advanced Vascular Imaging Ultrasound ProtocolsRecruitingNCT06841887
• Artificial Intelligence-based Image Processing Methods to Advance the Characterization of Polycystic Kidney DiseaseActive, not recruitingNCT06688981
• Medical Images Collection ResearchActive, not recruitingNCT06354829
• Multiparametric MRI in Healthy Volunteers and CKD PatientsActive, not recruitingNCT05229263Not applicable
• Dapagliflozin in Non-diabetic Stage IV CKDCompletedNCT04794517Phase 2
• SGLT2 Inhibitors in Glomerular HyperfiltrationWithdrawnNCT04143581Phase 2
• Tolvaptan-Octreotide LAR Combination in ADPKDCompletedNCT03541447Phase 2
• Remission Clinic in Proteinuric Chronic NephropathiesStatus unknownNCT02721342
• NEPHSTROM for Diabetic Kidney DiseaseTerminatedNCT02585622Phase 1/2
• Pulsed Perfusion for Marginal KidneysCompletedNCT02055950
• Sevelamer in Proteinuric CKDCompletedNCT01968759Phase 2
• Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal InsufficiencyCompletedNCT01377246Phase 3
• Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal InsufficiencyTerminatedNCT01223755Phase 2/3
• Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up StudyCompletedNCT00309283Phase 3
• Statins in Proteinuric NephropathiesCompletedNCT00199927Phase 3
• Renal and Systemic Effects of NCX4016 in Patients With Type 2 Diabetes and Early NephropathyTerminatedNCT00157508Phase 2